Literature DB >> 32602078

Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance.

D T W Lui1, C H Lee1, V W K Chau1, C H Y Fong1, K M Y Yeung1, J K Y Lam1, A C H Lee1, W S Chow1, K C B Tan1, Y C Woo2, K S L Lam3.   

Abstract

PURPOSE: Findings on trabecular bone score (TBS), an index of bone quality, have been reported in prediabetes defined by impaired fasting glucose or HbA1c. Here, we assessed the bone mineral density (BMD) and TBS in prediabetes individuals with impaired glucose tolerance (IGT), and investigated the association of these bone parameters with serum levels of fibroblast growth factor 21 (FGF21), a hormone implicated in bone metabolism and with higher levels in IGT.
METHODS: Chinese postmenopausal women aged 55-80 years, without diabetes, were recruited from the Hong Kong Cardiovascular Risk Factor Prevalence Study in 2016-2018. Normal glucose tolerance (NGT) was defined by fasting glucose < 5.6 mmol/L and 2-h plasma glucose (2hG) < 7.8 mmol/L, and IGT by 2hG 7.8-11 mmol/L. Serum levels of FGF21 and other bone metabolism regulators were measured. Insulin sensitivity was assessed by the Matsuda index. Independent determinants of TBS were evaluated using multivariable stepwise linear regression.
RESULTS: 173 individuals with NGT and 73 with IGT were included. TBS was lower in those with IGT compared to those with NGT, while BMD was comparable. Individuals with IGT had significantly higher serum FGF21 levels, which in turn showed an independent inverse relationship with TBS, attenuated after inclusion of the Matsuda index. Serum FGF21 levels, however, did not correlate with BMD.
CONCLUSION: Among Chinese postmenopausal women, bone quality was worse in IGT, despite comparable bone density. FGF21 levels showed a significant independent inverse relationship with TBS, partly attributed to insulin resistance. Whether FGF21 contributes to the impaired bone quality in IGT remains speculative.

Entities:  

Keywords:  Bone density; Chinese; Fibroblast growth factor 21; Hyperglycaemia; Insulin resistance; Osteoporosis; Prediabetes

Year:  2020        PMID: 32602078     DOI: 10.1007/s40618-020-01337-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  5 in total

Review 1.  The Role of Fibroblast Growth Factor 19 Subfamily in Different Populations Suffering From Osteoporosis.

Authors:  Xiawen Yu; Yue Xia; Jue Jia; Guoyue Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

2.  Comparison of Bone Mineral Density in US Adults With Diabetes, Prediabetes and Normoglycemia From 2005 to 2018.

Authors:  Jing Yuan; Pu Jia; Jian-Bo Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

3.  The Potential Role of Preoperative Trabecular Bone Score in Predicting Changes in Bone Mineral Density After Parathyroidectomy.

Authors:  David Tak Wai Lui; Matrix Man Him Fung; Chi Ho Lee; Carol Ho Yi Fong; Connie Hong Nin Loong; Allan Hoi Kin Lam; Kathryn Choon Beng Tan; Yu Cho Woo; Brian Hung Hin Lang
Journal:  World J Surg       Date:  2020-10-26       Impact factor: 3.352

4.  Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus.

Authors:  Dan Liu; Jing-Jie Bai; Jun-Jie Yao; Yong-Bo Wang; Tong Chen; Qian Xing; Ran Bai
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-29       Impact factor: 3.168

5.  The Relationship Between Prediabetes and Bone Mass in Adolescents: Analysis of the National Health and Nutrition Examination Survey From 2005 to 2010.

Authors:  Chun-Ming Ma; Fu-Zai Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-25       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.